Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Rituximab Maintenance in Lymphoma
NCT01665768Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2012
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in B cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL) and 6 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Safety as Assessed by Avoidance of Grade 3-4 Adverse Events at 3 years. Started Sep 2012; status: completed.
02
Drugs
everolimus
03
Conditions
B cell lymphomamantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)chronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT01665768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01665768.